172 related articles for article (PubMed ID: 23638745)
1. Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.
Baxevanis CN; Voutsas IF; Tsitsilonis OE
Immunotherapy; 2013 May; 5(5):497-511. PubMed ID: 23638745
[TBL] [Abstract][Full Text] [Related]
2. TLR Agonists as Adjuvants for Cancer Vaccines.
Li JK; Balic JJ; Yu L; Jenkins B
Adv Exp Med Biol; 2017; 1024():195-212. PubMed ID: 28921471
[TBL] [Abstract][Full Text] [Related]
3. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.
Chiang CL; Kandalaft LE; Coukos G
Int Rev Immunol; 2011; 30(2-3):150-82. PubMed ID: 21557641
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell immunotherapy for the treatment of neoplastic disease.
Decker WK; Xing D; Shpall EJ
Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.
Thomann JS; Heurtault B; Weidner S; Brayé M; Beyrath J; Fournel S; Schuber F; Frisch B
Biomaterials; 2011 Jul; 32(20):4574-83. PubMed ID: 21474175
[TBL] [Abstract][Full Text] [Related]
6. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
Conroy H; Marshall NA; Mills KH
Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
[TBL] [Abstract][Full Text] [Related]
7. Use of adjuvants for immunotherapy.
Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
[TBL] [Abstract][Full Text] [Related]
8. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
Front Immunol; 2020; 11():1112. PubMed ID: 32595636
[TBL] [Abstract][Full Text] [Related]
9. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
10. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer.
Seya T; Akazawa T; Uehori J; Matsumoto M; Azuma I; Toyoshima K
Anticancer Res; 2003; 23(6a):4369-76. PubMed ID: 14666723
[TBL] [Abstract][Full Text] [Related]
11. The future of toll-like receptor therapeutics.
Parkinson T
Curr Opin Mol Ther; 2008 Feb; 10(1):21-31. PubMed ID: 18228178
[TBL] [Abstract][Full Text] [Related]
12. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
Banday AH; Jeelani S; Hruby VJ
Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
[TBL] [Abstract][Full Text] [Related]
13. TLR based therapeutics.
Dunne A; Marshall NA; Mills KH
Curr Opin Pharmacol; 2011 Aug; 11(4):404-11. PubMed ID: 21501972
[TBL] [Abstract][Full Text] [Related]
14. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
Smits EL; Ponsaerts P; Berneman ZN; Van Tendeloo VF
Oncologist; 2008 Aug; 13(8):859-75. PubMed ID: 18701762
[TBL] [Abstract][Full Text] [Related]
15. Adjuvants for cancer vaccines.
Dubensky TW; Reed SG
Semin Immunol; 2010 Jun; 22(3):155-61. PubMed ID: 20488726
[TBL] [Abstract][Full Text] [Related]
16. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.
Chakraborty S; Ye J; Wang H; Sun M; Zhang Y; Sang X; Zhuang Z
Front Immunol; 2023; 14():1227833. PubMed ID: 37936697
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.
Kaur A; Kannan D; Mehta SK; Singh S; Salunke DB
Expert Opin Ther Pat; 2018 Nov; 28(11):837-847. PubMed ID: 30280939
[TBL] [Abstract][Full Text] [Related]
18. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction.
Smirnov D; Schmidt JJ; Capecchi JT; Wightman PD
Vaccine; 2011 Jul; 29(33):5434-42. PubMed ID: 21641953
[TBL] [Abstract][Full Text] [Related]
19. In vivo cancer vaccination: Which dendritic cells to target and how?
Chiang CL; Kandalaft LE
Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
[TBL] [Abstract][Full Text] [Related]
20. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.
Makkouk A; Abdelnoor AM
Immunopharmacol Immunotoxicol; 2009; 31(3):331-8. PubMed ID: 19555209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
